Choosing the Right P2Y12 Inhibitor After PCI – JAMA Cardiology
JAMA Cardiology shared a post on LinkedIn about a recent article by Giuseppe Biondi-Zoccai et al., adding:
“Editorial: A network meta-analysis of randomized clinical trials comparing clopidogrel, prasugrel, and ticagrelor in patients with Acute Coronary Syndrome (ACS) undergoing percutaneous coronary intervention (PCI) indicates that prasugrel offers the most favorable efficacy-safety profile for reducing major adverse cardiovascular events, myocardial infarction, and stent thrombosis.
Clinicians are advised that selection of a P2Y12 inhibitor should be individualized to account for patient comorbidities, bleeding risk, and concurrent therapies, with clopidogrel and ticagrelor remaining appropriate alternatives for specific scenarios.”
Title: Prasugrel – The Default P2Y12 Inhibitor After PCI for ACS?
Authors: Giuseppe Biondi-Zoccai, Salvatore Giordano, Nicola Corcione

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series